Selection of drugs to treat gastro-oesophageal reflux disease: The role of drug interactions

Clinical Pharmacokinetics

Volumn 39, Issue 4, 2000, Pages 295-309

  Flockhart, David A ^a   Desta, Zeruesenay ^a   Mahal, Subena K ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALUMINUM MAGNESIUM HYDROXIDE; ANTACID AGENT; ANTIBIOTIC AGENT; AZITHROMYCIN; CIMETIDINE; CISAPRIDE; ENOXACIN; ERYTHROMYCIN; FAMOTIDINE; FLUCONAZOLE; HALOPERIDOL; HISTAMINE H2 RECEPTOR ANTAGONIST; ITRACONAZOLE; KETOCONAZOLE; LANSOPRAZOLE; LOMEFLOXACIN; METOCLOPRAMIDE; NEUROLEPTIC AGENT; NIZATIDINE; OMEPRAZOLE; PANTOPRAZOLE; PHENOTHIAZINE DERIVATIVE; PROKINETIC AGENT; PROTON PUMP INHIBITOR; QUINOLONE DERIVATIVE; SOTALOL; TETRACYCLINE; UNINDEXED DRUG;

ASIAN; CAUCASIAN; DECISION MAKING; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; ENZYME INHIBITION; EXTRAPYRAMIDAL SYMPTOM; GASTROESOPHAGEAL REFLUX; HEART VENTRICLE ARRHYTHMIA; HUMAN; PRIORITY JOURNAL; REVIEW; WESTERN HEMISPHERE;

EID: 0033761045     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200039040-00005     Document Type: Review

References (126)

1. Bardhan KD. Duodenal ulcer and gastroesophageal reflux disease today: longterm therapy: a sideways glance. Yale J Biol Med 1996; 69: 211-24
2. Bremner CG, Bremner RM. Barren's esophagus. Surg Clin North Am 1997; 77: 1115-37
3. Reynolds JC. Influence of pathophysiology, severity, and cost on the medical management of gastroesophageal reflux disease. Am J Health Syst Pharm 1997; 53: S5-12
4. Castell DO. Gastro-esophageal reflux disease: current strategies for patient management. Arch Fam Med 1996; 5: 221-7
5. Blair DI, Kaplan B, Spiegler J. Patient characteristsics and lifestyle recommendations in the treatment of gastroesophageal reflux disease. J Fam Pract 1997; 44: 266-72
6. Fonkalsrud EW, Ament ME. Gastroesophageal reflux in childhood. Curr Probl Surg 1996; 33: 1-70
7. Ko J, Sukhova N, Thacker DL, et al. Evaluation of Omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos 1997; 25: 853-62
8. Flockhart DA. Drug interactions, cardiac toxicity, and terfenadine: from bench to clinic? J Clin Psychopharmacol 1996; 16: 101-3
9. Parkinson A. An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. Toxicol Pathol 1996; 24: 45-57
10. Laer S, Neumann J, Scholz H. Interaction between sotalol and an antacid preparation. Br J Clin Pharmacol 1997; 43: 269-72
11. Nix DE, Watson WA, Lener ME, et al. Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin. Clin Pharmacol Ther 1989; 46: 700-5
12. Grasela TH, Schentag JJ, Sedman AJ, et al. Inhibition of enoxacin absorption by antacids or ranitidine. Antimicrob Agents Chemother 1989; 33: 615-7
13. Jaehde U, Jorgel F, Stephan U, et al. Effect of an antacid containing magnesium and aluminum on absorption, metabolism, and mechanism of renal elimination of pcfloxacin in humans. Antimicrob Agents Chemother 1994; 38: 1129-33
14. Shimada J, Shiba K, Oguma T, et al. Effect of antacid on absorption of the quinolone lomefloxacin. Antimicrob Agents Chemother 1992; 36: 1219-24
15. Sullivan TJ, Reese JH, Jauregui L, et al. Short report: a comparative study of the interaction between antacid and H2 receptor antagonists. Aliment Pharmacol Ther 1994; 8: 123-6
16. Shelly DW, Doering PL, Russell WL, et al. Effect of concomitant antacid administration on plasma cimetidine concentrations during repetitive dosing. Drug Intell Clin Pharm 1986; 20: 792-5
17. Gaspari F, Vigano G, Locatelli M, et al. Influence of antacid administrations on aspirin absorption in patients with chronic renal failure on maintenance hemodialysis. Am J Kidney Dis 1988; 11:338-42
18. Hurwitz A, Schlozman DL. Effects of antacids on gastrointestinal absorption of isoniazid in rat and man. Am Rev Respir Dis 1974; 109:41-7
19. D'Arcy PF, McElnay JC. Drug-antacid interactions: assessment of clinical importance. Drug Intell Clin Pharm 1987; 21:607-17
20. Tatro DS. Tetracycline-antacid interactions. JAMA 1972; 220: 586-7
21. Lomaestro BM, Bailie GR. Absorption interactions with fluoroquinolones: 1995 update. Drug Saf 1995; 12: 314-33
22. Flor S, Guay DR, Opsahl JA, et al. Effects of magnesium-aluminum hydroxide and calcium carbonate antacids on bioavailability of ofloxacin. Antimicrob Agents Chemother 1990; 34: 2436-8
23. Barzaghi N, Gatti G, Crema F, et al. Impaired bioavailability of famotidine given concurrently with a potent antacid. J Clin Pharmacol 1989; 29: 670-2
24. Desager JP, Harvengt C. Oral bioavailability of nizatidine and ranitidine concurrently administered with antacid. J Int Med Res 1989; 17: 62-7
25. Sewell DD, Jeste DV. Metoclopramide associated tardive dys-kinesia: an analysis of 67 cases. Arch Fam Med 1992; 1:271-8 '
26. Miller LG, Jankovic J. Metoclopramide induced movement disorders: clinical findings with a review of the literature. Arch Intern Med 1989; 149: 2486-92
27. Feldman S, Karalliedde L. Drug interactions with neuromuscular blockers. Drug Saf 1996; 15: 261-73
28. Oilman TM, Segal JL, Brunnemann SR. Metoclopramide increases the bioavailability of dantrolene in spinal cord injury. J Clin Pharmacol 1996; 36: 64-71
29. Yee GC, McGuire TR. Pharmacokinetic drug interactions with cyclosporin (part I). Clin Pharmacokinet 1990; 19: 319-32
30. Fumagalli I, Hammer B. Cisapride versus metoclopramide in the treatment of functional dyspepsia: a double blind comparative trial. Scand J Gastroenterol 1994; 29: 33-7
31. Robinson M. Prokinetic therapy for gastroesophageal reflux disease. Am Fam Physician 1995; 52: 957-62
32. Bonet-Pons MA, Herrero-Ambrosio A, Recuero-Alonso RM, et al. Cisapride: a new gastrointestinal prokinetic agent. Farm Clin 1991; 8: 336-45
33. Bennett JR. How safe and acceptable is cisapride? Scand J Gastroenterol 1989; 24: 59-61
34. Davies DS, Mills FJ, Welburn PJ. Cisapride has no effect on antipyrine clearance. Br J Clin Pharmacol 1988; 26: 808-9
35. May B, Greving I. Pharmacologic and clinical differentiation of prokinetic drugs. Leber Magen Darm 1996; 26: 193-8
36. Ahmad SR, Wolfe SM. Cisapride and torsades de pointes [let- , ter]. Lancet 1995; 345: 508
37. Wysowski DK, Bacsanyi J. Cisapride and fatal arrhythmia [let- | ter]. N Engl J Med 1996; 335: 290-1
38. Dunbar F. Cisapride labelling change [letter]. S Afr Med J 1995; 85d: 287-8
39. Anonymous. Cisapride drug interactions can be fatal. Drugs Ther Perspect 1997; 9: 11 -3
40. Bedford TA, Rowbotham DJ. Cisapride: drug interactions of clinical significance. Drug Saf 1996; 15: 167-75
41. Premji SS, Paes B. Cisapride: the problem of the heart. Neonatal Netw 1999; 18: 21-5
42. Kirch W, Janisch HD, Ohnhaus EE, et al. Cisapride-cimetidine interaction: enhanced cisapride bioavailability and accelerated cimetidine absorption. Ther Drug Monit 1989; 11:411-4
43. Kirch W, Janisch HD, Ohnhaus EE, et al. Cisapride-cimetidine interaction: enhanced cisapride bioavailability and accelerated cimetidine absorption. Ther Drug Monit 1989; 11 (4): 411-4
44. Rowbotham DJ, Milligan K, McHugh P. Effect of single doses of cisapride and ranitidine administered simultaneously on plasma concentrations of cisapride and ranitidine. Br J Anaesth 1991:67:302-5
45. Milligan KA, McHugh P, Rowbotham DJ. Effects of concomitant administration of cisapride and ranitidine on plasma concentrations in volunteers [abstract]. Br J Anaesth 1989; 63:628P
46. Carlsson L, Amos GJ, Andersson B, et al. Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: implications for proarrythmic potential? J Pharmacol Exp Ther 1997; 282: 220-7
47. Kii Y, Ito T. Effects of 5-HT4-receptor agonists, cisapride, mosapride citrate and zacopride on cardiac action potentials in guuinea pig isolated papillary muscles. J Cardiovasc Pharmacol 1997; 29: 670-5
48. Desta Z, Soukhova N, Mahal S, et al. Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies. Drug Metab Dispos 2000; 28: 789-800
49. Honig PK, Woosley RL, Zamani K, et al. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992;52:231-8
50. Tierney MG, Uhthoff TL, Kravcik S, et al. Potential cisaprideerythromycin interaction. Can J Clin Pharmacol 1997; 4:82-4
51. Jenkins IR, Gibson J. Cisapride, erythromycin and arrhythmia [letter]. Anaesth Intensive Care 1997; 25: 318-9
52. Chan-Thompkins NH, Babinchak TJ. Cardiac arrhythmias associated with coadministration of azole compounds and cisapride [letter]. Clin Infect Dis 1997; 24: 1285
53. Honig PK, Wortham DC, Zamani K, et al. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA 1993; 269: 1513-8
54. Honig PK, Wortham DC, Hull R, et al. Itraconazole affects single dose terfenadine pharmacokinetics and cardiac repolarization phannacodynamics. J Clin Pharmacol 1993; 33: 1201-6
55. Honig PK, Wortham DC, Zamani K, et al. The effect of fluconazole on the steady-state pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine in humans. Clin Pharmacol Ther 1993; 53: 630-6
56. Honig PK, Wortham DC, Zamani K, et al. Effect of concominant administration of cimetidine and ranitidine on the pharmacokinetics and electrocardiographic effects of terfenadine. Eur J Clin Pharmacol 1993:45:41-6
57. Benton R, Honig PK, Zamani K, et al. Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. Clin Pharmacol Ther 1996:59:383-8
58. Honig PK, Wortham DC, Zamani K, et al. Comparison of the effect of the macrolide antibiotics erythromycin, clarithromycin and azithromycin on terfenadine steady-state pharmacokinetics and electrocardiographic parameters. Drug Invest 1994; 7: 148-56
59. Hanrahan JP, Choo PW, Carlson W, et al. Terfenadine-associated ventricular arrhythmias and QTc interval prolongation: a retrospective cohort comparison with other antihistamines among members of a health maintenance organization. Ann Epidemiol 1995; 5: 201-9
60. Gueugniaud PY, Guerin C, Mahul P, et al. Torsades de pointe induites par l'association lidocaine-erythromycine et unsuffisance hepatique. Presse Med 1985; 14: 896-7
61. Freedman RA, Anderson KP, Green LS, et al. Effect of erythromycin on ventricular arrhythmias and ventricular repolarization in idiopathic long QT syndrome. Am J Cardiol 1987; 59: 168-9
62. McComb JM, Campbell NPS, Cleland J. Recurrent ventricular tachycardia associated with QT prolongation after mitral valve replacement and its association with intravenous administration of erythromycin. Am J Cardiol 1984; 54: 922-3
63. Guelon D, Bedock B, Chartier C, et al. QT prolongation and recurrent 'torsades de pointes' during erythromycin lactobionate infusion. Am J Cardiol 1986; 58: 666
64. Wager E, Tolley PJH, Pearce GL, et al. A comparison of two cohort studies evaluating the safety of cisapride: prescriptionevent monitoring and a large phase IV study. Eur J Clin Pharmacol 1997; 52: 87-94
65. Bateman DN. The action of cisapride on gastric emptying and the pharmacodynamics and pharmacokinetics of oral diazepam. Eur J Clin Pharmacol 1986; 30: 205-8
66. Bateman DN. Effects of cisapride on gastric emptying and diazepam absorption in man. Br J Clin Pharmacol 1986; 21: 121P-2P
67. Roine R, Heikkonen E, Salaspuro M. Cisapride enhances alcohol absorption and leads to high blood alcohol levels [abstract]. Gastroenterology 1992; 102: A507
68. Andrejak M, Hary L, Westeel PF, et al. Effects of cisapride on the intestinal absorption of cyclosporine in renal transplant recipients [abstract]. Fundam Clin Pharmacol 1991; 5:467
69. Campana C, Regazzi MB, Buggia I, et al. Clinically significant drue interactions with cyclosporin: an update. Clin Pharmacokinet 1996;30: 141-79
70. Diaz-Neira W, Sanchez V, Angeles-Mena M, et al. The effects of cisapride on plasma L-dopa levels and clinical response in Parkinson's disease. Mov Disord 1995; 10: 66-70
71. Rowbotham DJ, Milligan K, McHugh P. Effect of cisapride on morphine absorption after oral administration of sustainedrelease morphine. Br J Anaesth 1991; 67:421-5
72. Satoh C, Sakai T, Kashiwagi H, et al. Influence of cisapride on the pharmacokinetics and antihypertensive effect of sustained-release nifedipine. Intern Med 1996; 35: 941-5
73. Satoh C. Effect of cisapride on pharmacokinetics and the antihypertensive action of sustained-release preparations of nifedipine. Tokyo Jikeikai Med J 1994; 109: 933-42
74. Roberts GW, Kowalski SR, Calabretto JP. Lack of effect of cisapride on phenytoin free fraction. Ann Pharmacother 1992; 26: 1016-7
75. Sellers EM. Plasma protein displacement interactions are rarely of clinical significance. Pharmacology 1979; 18: 225-7
76. Ketter TA, Flockhart DA, Post RM, et al. The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol 1995; 15: 387-98
77. Ishida M, Otani K, Yasui N, et al. Possible interaction between cisapride and bromperidol. Prog Neuropsychopharmacol Biol Psychiatry 1997; 21: 235-8
78. Zwillich ZW, Sutton FDJ, Teff TA, et al. Theophylline-induced seizures in adults: correlation with serum concentrations. Ann Intern Med 1975; 82: 784-7
79. Jackson JE, Powell JR, Wandell M, et al. Cimetidine decreases theophylline clearance. Am Rev Respir Dis 1981; 123:615-7
80. Weinberger MM, Smith G, Milavetz G, et al. Decreased theophylline clearance due to cimetidine. N EngI J Med 1981 ; 304: 672
81. Bauman JH, Kimelblatt BJ, Caraccio TR, et al. Cimetidinetheophylline interaction: report of four patients. Ann Allergy 1982; 48: 100-2
82. Roberts RK, Grice J, McGuffie C. Cimetidine-theophylline interaction in patients with chronic obstructive airways disease. Med JAust 1984; 140: 279-80
83. Powell JR. Inhibition of theophylline clearance by cimetidine but not ranitidine. Arch Intern Med 1997; 144: 484-6
84. Cohen IA, Johnson CE, Berardi RR, et al. Cimetidine-theophylline interaction: effects of age and cimetidine dose. Ther Drug Monit 1965:7:426-34
85. McEwen J, McMurdo ME, Moreland TA. The effects of oncedaily dosing with ranitidine and cimetidine on theophylline pharmacokinclics. Eur J Drug Metab Pharmacokinet 1988; 13:201-5
86. Greenblatt D J, Abernethy DR, Morse DS, et al. Clinical importance of the interaction of diazepam and cimetidine. N Engl J Med 1984; 310: 1639-43
87. Klotz U, Arvela P, Rosenkranz B. Effect of single doses of cimetidine and ranitidine on the steady-state plasma levels of midazolam. Clin Pharmacol Ther 1985; 38: 652-5
88. Sanders LD, Whitehead C, Gildersleve CD, et al. Interaction of H2-receptor antagonists and benzodiazepine sedation: a double-blind placebo-controlled investigation of the effects of cimetidine and ranitidine on recovery after intravenous midazolam. Anaesthesia 1993; 48:286-92
89. Mutschler E, Spahn H, Kirch W. The interaction between 112receptor antagonists and beta-adrenoceptor blockers. Br J Clin Pharmacol 1984; 17 Suppl.: 51S-57S
90. Feely J, Wilkinsin GR, Wood AJJ. Reduction ofliver blood flow and propranolol metabolism by cimetidine. N Engl J Med 1981; 304: 692-5
91. Toon S, Davidson EM, Garstang FM, et al. The racemic metoprolol H2-antagonist interaction. Clin Pharmacol Ther 1988; 43:283-9
92. Ellis ME, Hussain M, Webb AK, et al. The effect of cimetidine on the relative cardioselectivity of atenolol and metoprolol in asthmatic patients. Br J Clin Pharmacol 1984; 17: 59S-64S
93. Neuvonen PJ, Tokola RA, Kaste M. Cimetidine-phenytoin interaction: effect on serum phenytoin concentration and antipyrine test. Eur J Clin Pharmacol 1981 ; 21: 215-20
94. Hetzel DJ, Bochner F, Hallpike JF, et al. Cimetidine interaction with phenytoin [letter]. BMJ 1981; 282: 1512
95. Bramhall D, Levine M. Possible interaction of ranitidine with phenytoin. Drug Intell Clin Pharm 1988; 22: 979-80
96. Lelawongs P, Barone JA, Colaizzi JL, et al. Effect of food and gastric acidity on absorption of orally administered ketoconazole. Clin Pharm 1988; 7: 228-35
97. Tanaka M, Ohkubo T, Otani K, et al. Metabolie disposition of pantoprazole, a proton pump inhibitor, in relation to Smephenytoin 4'-hydroxylation phenotype and genotype. Clin Pharmacol Ther 1997; 62: 619-28
98. Balian JD, Sukhova N, Harris JW, et al. The hydroxylation of omeprazole correlates with 5-mephenytoin metabolism: a population study. Clin Pharmacol Ther 1995; 57: 662-9
99. Sohn D-R, Kwon J-T, Kim H-K, et al. Metabolic disposition of lansoprazole in relation to the 5-mephenytoin 4'-hydrox-yIationphenotypestatus.ClinPharmacolTher l997;61:57482
100. Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors: focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 1996; 31: 9-28
101. Pearce RE, Rodrigues AD, Goldstein JA, et al. Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther 1996; 277: 805-16
102. Andersson T, Miners JO, Veronese ME, et al. Identification of human liver chromosome P450 isoforms mediating omeprazole metabolism. Br J Glin Pharmacol 1993; 36: 521-30
103. Rost KL, Brosicke H, Heinemeyer G, et al. Specific and dosedependent enzyme induction by omeprazole in human beings. Hepatology 1994; 20: 1204-12
104. Cavuto NJ, Flockhart DA. Effect of omeprazole on theophylline clearance in poor metabolizers of omeprazole [abstract]. Clin Pharmacol Ther 1995; 57: 215
105. Ko JW, Jang IJ, Shin JG, et al. Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers. Clin Pharmacol Ther 1999 Jun; 65 (6): 606-14
106. Andersson T, Cederberg C, Evardsson G, et al. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin Pharmacol Ther 1990; 47: 79-85
107. Lefebvre RA, Flouvat B, Karolac-Tamisier S. Influence of lansoprazole treatment on diazepam plasma concentrations. Clin Pharmacol Ther 1992; 52: 458-63
108. Gugler R, Hartmann M, Rudi J, et al. Lack of pharmacokinelic interaction of pantoprazole with diazepam in man. Br J Clin Pharmacol 1996; 42: 249-52
109. Bajpai M, Roskos LK, Shen DD, et al. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab Dispos 1996; 24: 1401-3
110. Donahue S, Abernethy DR, Flockhart DA, et al. Mechanism of phenytoin toxicity in a patient taking ticlopidine. Clin Pharmacol Ther 1997; 62:572-7
111. Prichard PJ, Walt RP, Kitchingham GK, et al. Oral phenytoin pharmacokinetics during omeprazole therapy. Br J Clin Pharmacol 1987; 24: 543-5
112. Andersson T, Lagerstfom PO, Unge P. A study of the interaction between omeprazole and phenytoin in epileptic patients. Ther Drug Monitor 1990; 12: 329-33
113. Landes BD, Petite JP, Flouvat B. Clinical pharmacokinetics of lansoprazole. Clin Pharmacokinet 1996; 28: 458-70
114. Karol MD, Mukherji D, Cavanaugh JH. Lack of effect of concomitant multi-dose lansoprazole on single dose phenytoin pharmacokinetics [abstract]. Gastroenterology 1994; 106 ' Suppl.: 103
115. Middle MV, Muller FO, Schall R, et al. No influence of pantoprazole on the pharmacokinetics of phenytoin. Int J Clin Pharmacol Ther 1996; 34: S72-5
116. Bertilsson L, Tybring G, Widen J, et al. Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via C YP2C19. Br J Clin Pharmacol 1998; 44: 186-9
117. Dammann HG. Therapy with omeprazole and clarithromycin increases serum carbamazepine levels in patients with H. pylori gastritis [letter]. Dig Dis Sei 1996; 41: 519-20
118. Metz DC, Geiz HD. Helicobacterpylori gastritis therapy with omeprazole and clarithromycin increases serum carbamazepine levels. Dig Dis Sei 1995; 40: 912-5
119. Ahmad S. Omeprazole-warfarin interaction [letter]. South Med J 1991:84:674-5
120. Black DJ, Kunze KL, Wienkers LC, et al. A metabolically based drug interaction between fluconazole and warfarin: in vivo studies. Drug Metab Dispos 1996; 24: 422-8
121. Rettie AE, Korzekwa KR, Kunze KL, et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (5)-warfarin-drug interactions. Chem Res Toxicol 1992; 5: 54-9
122. Unge P, Svedberg LE, Nordgren A, et al. A study of the interaction of omeprazole and warfarin in anticoagulated patients. Br J Clin Pharmacol 1992; 34:509-12
123. Unge P, Andersson T. Drug interactions with proton pump inhibitors. DrugSaf 1997; 16: 171-9
124. Steinijans VW, Huber R, Hartmann MZ, et al. An updated review of pantoprazole drug interactions in man. Verdauungskrankheiten 1997; 15: 77-96
125. Meyer UA. Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions. Yale J Biol Med 1996;69:203-9
126. Marcuard SP, Albemaz L, Khazanie PG. Omeprazole therapy causes malabsorption of cyanocobalamin. Ann Intern Med 1994; 120:211-5